212 related articles for article (PubMed ID: 16862573)
1. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
Nakabayashi M; Xie W; Regan MM; Jackman DM; Kantoff PW; Oh WK
Cancer; 2006 Sep; 107(5):975-81. PubMed ID: 16862573
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
Scholz M; Jennrich R; Strum S; Brosman S; Johnson H; Lam R
J Urol; 2005 Jun; 173(6):1947-52. PubMed ID: 15879788
[TBL] [Abstract][Full Text] [Related]
3. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
[TBL] [Abstract][Full Text] [Related]
6. Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature.
Madan RA; Lieberman R; Gulley JL; Dahut W; Arlen PM
Am J Ther; 2007; 14(3):310-3. PubMed ID: 17515709
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
8. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
Small EJ; Halabi S; Dawson NA; Stadler WM; Rini BI; Picus J; Gable P; Torti FM; Kaplan E; Vogelzang NJ
J Clin Oncol; 2004 Mar; 22(6):1025-33. PubMed ID: 15020604
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.
Wilkinson S; Chodak G
Eur Urol; 2004 May; 45(5):581-4; discussion 585. PubMed ID: 15082199
[TBL] [Abstract][Full Text] [Related]
10. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of low dose ketoconazole therapy for Chinese patients with castration resistant prostate cancer].
Lin GW; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Ma CG; Xiao WJ; Qin XJ
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):520-3. PubMed ID: 22490153
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
13. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
Small EJ; Baron AD; Fippin L; Apodaca D
J Urol; 1997 Apr; 157(4):1204-7. PubMed ID: 9120902
[TBL] [Abstract][Full Text] [Related]
14. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
Figg WD; Liu Y; Arlen P; Gulley J; Steinberg SM; Liewehr DJ; Cox MC; Zhai S; Cremers S; Parr A; Yang X; Chen CC; Jones E; Dahut WL
J Urol; 2005 Mar; 173(3):790-6. PubMed ID: 15711271
[TBL] [Abstract][Full Text] [Related]
15. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
[TBL] [Abstract][Full Text] [Related]
16. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
Daliani DD; Assikis V; Tu SM; Papandreou CN; Pagliaro LC; Holtkamp T; Wang X; Thall PF; Logothetis CJ
Cancer; 2003 Feb; 97(3):561-7. PubMed ID: 12548597
[TBL] [Abstract][Full Text] [Related]
18. Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma.
Shulman MJ; Benaim EA
Cancer; 2005 Jun; 103(11):2280-6. PubMed ID: 15844202
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
20. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.
Amato RJ; Teh BS; Henary H; Khan M; Saxena S
Urol Oncol; 2009; 27(2):165-9. PubMed ID: 18367115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]